Immx.O

Immix Biopharma maintains a strong liquidity position with $93.9 million in cash and equivalents against total liabilities of $11.0 million, resulting in a debt-to-equity ratio of 0.0. The company holds total assets of $104.8 million and total equity of $93.8 million, indicating a conservative capital structure with no long-term debt burden. Operating cash flow is negative at -$23.9 million, reflecting the cash-intensive nature of its pre-revenue or early-stage operations.

The company is currently unprofitable, reporting a net income loss of -$29.4 million and an operating income loss of -$29.9 million. Return on equity stands at -31.39% and return on assets at -28.08%, consistent with a biotechnology firm investing heavily in research and development before achieving commercial scale. These negative returns are typical for the sector but highlight the absence of current profitability drivers.

Revenue mix and geographic exposure data are not available in the provided financial snapshot, preventing a detailed analysis of segment concentration or regional risk. The company’s structure includes subsidiaries such as Nexcella, Inc, Immix Biopharma Immunology, Inc, and Immix Biopharma Australia Pty Ltd, suggesting a global operational footprint.

Historical growth trajectory data is absent from the input, limiting the ability to assess revenue trends or net income progression over time. The current financial snapshot indicates a single period of significant operating losses, which is characteristic of early-stage biotech firms that have not yet launched commercial products.

Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The company’s substantial cash reserve relative to its liabilities provides a buffer against near-term solvency concerns, although the negative operating cash flow implies a gradual depletion of cash reserves if profitability is not achieved.

Recent observations include reconciler events related to analysis job processing for Immix Biopharma Inc, but no specific news events, filing observations, or transcript insights are provided to detail recent corporate actions or strategic shifts. The lack of recent material events suggests a period of operational stability without major public disclosures.